Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP101 in Children With ASD and GI Symptoms
NCT03829878Phase 2Withdrawn
- Sponsor
- Finch Therapeutics
- Start
- May 2020
- Primary completion
- May 2020
- Modality
- Live Biotherapeutic Products
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) and gastrointestinal disorders comparing CP101 Arm with Placebo Arm (2 arms). Primary endpoint: Childhood Autism Rating Scales-2 at 24 weeks. Planned start May 2020; status: withdrawn.
02
Drugs
CP101
03
Conditions
Autism Spectrum Disorder (ASD)gastrointestinal disorders
Beyond the preview
Go deeper on NCT03829878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829878.